|
Alburquerque-Gonzalez B, Bernabe-Garcia A, Bernabe-Garcia M, Ruiz-Sanz J, Lopez-Calderon FF, Gonnelli L, Banci L, Pena-Garcia J, Luque I, Nicolas FJ, Cayuela-Fuentes ML, Luchinat E, Perez-Sanchez H, Montoro-Garcia S, Conesa-Zamora P. The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. Cancers (Basel). 2021 Feb 18;13(4):861. doi: 10.3390/cancers13040861. PubMed PMID: 33670655; PubMed Central PMCID: PMC7921938.
AÑO: 2021; IF: 6.575
|
|
Santaclara V, Torres-Moreno D, Bernal-Manas CM, Isaac MA, Ortiz-Reina S, Conesa-Zamora P. Relationship between polymorphisms in the FAS/FASL death receptor system and progression of low-grade precursor lesions infected with high-risk human papilloma virus. Hum Immunol. 2021 Sep;82(9):621-624. doi: 10.1016/j.humimm.2021.06.002. Epub 2021 Jun 12. PubMed PMID: 34127318.
AÑO: 2021; IF: 2.211
|
|
Turpin-Sevilla MDC, Perez-Sanz F, Garcia-Solano J, Sebastian-Leon P, Trujillo-Santos J, Carbonell P, Estrada E, Tuomisto A, Herruzo I, Fennell LJ, Makinen MJ, Rodriguez-Braun E, Whitehall VLJ, Conesa A, Conesa-Zamora P. Global Methylome Scores Correlate with Histological Subtypes of Colorectal Carcinoma and Show Different Associations with Common Clinical and Molecular Features. Cancers (Basel). 2021 Oct 14;13(20):5165. doi: 10.3390/cancers13205165. PubMed PMID: 34680315; PubMed Central PMCID: PMC8533997.
AÑO: 2021; IF: 6.575
|
|
de Alarcon R, Alburquerque-Gonzalez B, Fernandez-Valera A, Molina-Nunez M, Alvarez Fernandez G, Consuegra-Sanchez L, Luengo-Gil G, Conesa-Zamora P. Pharmacogenetic role of vitamin D-binding protein and vitamin D receptor polymorphisms in the treatment response of dialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2022 Mar 25;37(4):792-795. doi: 10.1093/ndt/gfab353. No abstract available. PubMed PMID: 34888693.
AÑO: 2022; IF: 6.1
|
|
Luengo-Gil, Gines; Conesa-Zamora, Pablo. Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response. GLOBAL CHALLENGES. 2021; . 10.1002/gch2.202100051
AÑO: 2021; IF: 5.135
|